Funder
Instituto de Salud Carlos III
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference27 articles.
1. Hauser SL, Waubant E, Arnold DL et al (2008) B cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688. https://doi.org/10.1056/NEJMOA0706383
2. Bar-Or A, Calabresi PAJ, Arnlod D et al (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63:395–400. https://doi.org/10.1002/ANA.21363
3. Naismith RT, Piccio L, Lyons JA et al (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis. Neurology 74:1860–1867. https://doi.org/10.1212/WNL.0B013E3181E24373
4. Ocrevus | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus. Accessed 7 Nov 2021
5. Therapeutic positioning report of ocrelizumab (Ocrevus ®) in multiple sclerosis , January 15 ,2019 (v.1). In: Spanish Agency Med. Med. Devices. https://www.aemps.gob.es/medicamentos-de-uso-humano/informes-de-posicionamiento-terapeutico/#L04-Inmunosupresores
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献